Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Vorsetuzumab mafodotin
Подписчиков: 0, рейтинг: 0
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | CD70 |
Clinical data | |
Other names | SGN-75 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6476H10006N1726O2028S50(C49H78N6O11)3-5 |
Molar mass | 150 kg/mol |
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer. It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.
This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma, but development was discontinued in 2013. No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.
Chemokine |
|
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CSF |
|
||||||||||||
Interferon |
|
||||||||||||
Interleukin |
|
||||||||||||
TGFβ |
|
||||||||||||
TNF |
|
||||||||||||
Others |
|